Evidence map›Paper›PMID 38831124›Full record

ArticleCancer reports (Hoboken, N.J.)2024

Clinicopathological features of hepatoid adenocarcinoma of the stomach: A multicenter retrospective study.

Senichiro Yanagawa, Kazuaki Tanabe, Mikihiro Kano, Ryuichi Hotta, Yoshihiro Saeki, Nobuaki Fujikuni, Hideki Ohdan, Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Senichiro YanagawaDepartment of Surgery, JA Onomichi General Hospital, Hiroshima, Japan.ORCID 0000-0002-3076-8622
Kazuaki TanabeDepartment of Perioperative and Critical Care Management, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0000-0002-8650-2735
Mikihiro KanoDepartment of Surgery, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan.
Ryuichi HottaDepartment of Surgery, National Hospital Organization Higashihiroshima Medical Center, Higashihiroshima, Japan.
Yoshihiro SaekiDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Nobuaki FujikuniDepartment of Digestive Surgery, Hiroshima Prefectural Hospital, Hiroshima, Japan.ORCID 0009-0009-8702-6601
Hideki OhdanDepartment of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatoid adenocarcinoma of the stomach (HAS) is a rare and aggressive subtype of gastric cancer (GC), accounting for less than 1% of all cases. It is characterized by frequent liver metastasis recurrence and a poorer prognosis than conventional GC. However, established treatment guidelines for HAS are currently not available.In this report, we present the results of a clinicopathological study of 19 patients diagnosed with HAS, including seven patients with liver metastasis, conducted by the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO) between 2016 and 2018.

aimsThe aim of the study was to retrospectively observe the outcomes of HAS with gastrectomy and hepatectomy for liver metastasis and determine relevant prognostic factor. We also examined the criteria and outcomes of hepatectomy for liver metastasis and aimed to suggest the optimal treatment for HAS, including chemotherapy. METHODS AND

resultsA total of 2147 patients underwent gastrectomy for GC at HiSCO-affiliated institutions during the study period; 19 patients, all male with a mean age of 70.9 years, were diagnosed with HAS by hematoxylin-eosin and immunohistochemical staining. Patients underwent gastrectomy at varying pathological stages: six at Stage I, three at Stage II, seven at Stage III, and three at Stage IV. Ten patients received postoperative chemotherapy and the 5-year survival rate was 67.7% after gastrectomy. Among the seven patients with pre or postoperative liver metastasis, five patients underwent hepatectomy. Although one patient had recurrence, the 3-year survival rate was 100% after hepatectomy.

conclusionContrary to previous reports suggesting a 3-year survival rate of approximmately 30% for HAS, our findings indicate that the prognosis for HAS may not be as poor as reported previously. This study contributes valuable insights into the management and potential treatment strategies for HAS.

Indexed as

AdenocarcinomaGastrectomyHepatectomyLiver NeoplasmsStomach NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRetrospective StudiesSurvival Ratechemotherapygastrectomyhepatectomyhepatoid adenocarcinoma of the stomachliver metastasis

Identifiers

PMID38831124
PMCPMC11147685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.